An official website of the United States government
Home
Name
Romvimza
Alternate Names
Vimseltinib
Abbreviations
None
Category
Chemotherapy
Subcategory
Kinase inhibitor
NSC Number
None
Primary Site
None
Histology
Giant cell tumor
Remarks
February 14, 2025 FDA approved vimseltinib (Romvimza) a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
Coding
This drug should be coded
